Deanna Rankin, OD
Optometrist · Greenwood, INNPI 1407548555
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.2%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. Alcon accounts for 84.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,462 and has fallen 85.3% since, to $215 in 2025.
Across 21 payments — averaging $81.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Tarsus Pharmaceuticals, Inc.$138
- Johnson & Johnson Vision Care, Inc.$63
- Optos, Inc.$39
- Sun Pharmaceutical Industries Inc.$15
- Lombart Brothers, Inc.$11
Across 25 payments — averaging $32.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$810
What the payments were for
- Travel & lodging$92754%
- Food & beverage$74544%
- Entertainment$392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $1,445 |
| Tarsus Pharmaceuticals, Inc. | 7 | $138 |
| Johnson & Johnson Vision Care, Inc. | 3 | $63 |
| Optos, Inc. | 1 | $39 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Lombart Brothers, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,710 in reported general payments places this provider in the 75th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $23,252 |
| VyzultaLatanoprostene Bunod | 16 | $4,591 |
| Latanoprost | 36 | $388 |
| Brimonidine Tartrate | 13 | $125 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Greenwood
- Christopher BrowningGreenwood$28K
- Damon DierkerIndianapolis$707K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Rhonda RobinsonIndianapolis$205K
- John CzajaMerrillville$189K
- Peter KollbaumBloomington$60K
- Ryan GustusBluffton$48K
- Steve VargoHighland$48K
- Helen TzanetakosMunster$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.